Antisoma buys out Imperial Cancer stake in Cancer Therapeutics Ltd
This article was originally published in Clinica
Executive Summary
Antisoma, the London-based biopharmaceuticals company which is developing an epithelially preferential contrast agent, has bought out its research partner's share in Cancer Therapeutics (CTL).